GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revolution Medicines Inc (NAS:RVMD) » Definitions » 9-Day RSI

Revolution Medicines (Revolution Medicines) 9-Day RSI : 57.66 (As of Apr. 29, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Revolution Medicines 9-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-04-29), Revolution Medicines's 9-Day RSI is 57.66.

The industry rank for Revolution Medicines's 9-Day RSI or its related term are showing as below:

RVMD's 9-Day RSI is ranked worse than
81.63% of 1573 companies
in the Biotechnology industry
Industry Median: 44.52 vs RVMD: 57.66

Competitive Comparison of Revolution Medicines's 9-Day RSI

For the Biotechnology subindustry, Revolution Medicines's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revolution Medicines's 9-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revolution Medicines's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where Revolution Medicines's 9-Day RSI falls into.



Revolution Medicines  (NAS:RVMD) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revolution Medicines  (NAS:RVMD) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Revolution Medicines 9-Day RSI Related Terms

Thank you for viewing the detailed overview of Revolution Medicines's 9-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Revolution Medicines (Revolution Medicines) Business Description

Traded in Other Exchanges
Address
700 Saginaw Drive, Redwood City, CA, USA, 94063
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Executives
Stephen Michael Kelsey officer: See Remarks C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Jeff Cislini officer: General Counsel C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mark A Goldsmith director, officer: See Remarks 925 PAGE MILL ROAD, PALO ALTO CA 94304
Margaret A Horn officer: See Remarks 925 PAGE MILL ROAD, PALO ALTO CA 94304
Jack Anders officer: Chief Financial Officer C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Barbara Weber director C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Xiaolin Wang officer: See Remarks C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Thilo Schroeder director C/O NEXTECH INVEST LTD., BAHNHOFSTRASSE 18, ZURICH V8 8001
Lorence H. Kim director C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Sushil Patel director C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK, THIRD FLOOR, WOBURN MA 01801
Third Rock Ventures Iii, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Flavia Borellini director C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Third Rock Ventures Ii, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Peter Svennilson director, 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Vincent A. Miller director C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139